Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for Intellia Therapeutics (NTLA) over the last 11 years, with Q3 2025 value amounting to $925.3 million.

  • Intellia Therapeutics' Liabilities and Shareholders Equity fell 2114.25% to $925.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.0 billion, marking a year-over-year decrease of 1876.18%. This contributed to the annual value of $1.2 billion for FY2024, which is 845.23% down from last year.
  • Intellia Therapeutics' Liabilities and Shareholders Equity amounted to $925.3 million in Q3 2025, which was down 2114.25% from $898.9 million recorded in Q2 2025.
  • In the past 5 years, Intellia Therapeutics' Liabilities and Shareholders Equity ranged from a high of $1.5 billion in Q4 2022 and a low of $672.2 million during Q2 2021
  • In the last 5 years, Intellia Therapeutics' Liabilities and Shareholders Equity had a median value of $1.2 billion in 2024 and averaged $1.1 billion.
  • As far as peak fluctuations go, Intellia Therapeutics' Liabilities and Shareholders Equity soared by 19112.34% in 2021, and later plummeted by 2456.01% in 2025.
  • Quarter analysis of 5 years shows Intellia Therapeutics' Liabilities and Shareholders Equity stood at $1.3 billion in 2021, then rose by 17.43% to $1.5 billion in 2022, then fell by 14.42% to $1.3 billion in 2023, then dropped by 8.45% to $1.2 billion in 2024, then dropped by 22.31% to $925.3 million in 2025.
  • Its Liabilities and Shareholders Equity stands at $925.3 million for Q3 2025, versus $898.9 million for Q2 2025 and $986.2 million for Q1 2025.